Sinopep-Allsino Biopharmaceutical Co., Ltd.
↗Hangzhou, China
Sinopep-Allsino is a leading worldwide commercial API supplier and full-service CDMO (Contract Development and Manufacturing Organization) delivering large-scale GMP manufacturing for peptides, oligonucleotides, and small molecules. The company serves global biopharma partners from development through commercial supply, specializing in therapeutic peptides and advanced pharmaceutical ingredients. With over 20 years of expertise in pharmaceutical manufacturing, the company operates under both GMP and non-GMP conditions and serves major pharmaceutical clients across the US, Europe, Japan and other developed markets.
CLASSIFICATION
SIZE & FINANCIALS
Employees:501-1000
Revenue:$200M-$400M (estimate based on operations)
Founded:2009
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
STOCK
Exchange:Shanghai Stock Exchange - STAR Market
Ticker:688076
Market Cap:~$1.8 billion (as of 2025)
PIPELINE
Stage:Commercial
Lead Drug Stage:CDMO Services (not drug developer)
Modalities:Peptides, Small molecules, Oligonucleotides, ASOs, siRNA, Advanced conjugates
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Allsino Pharmaceutical Co., Ltd. (100% subsidiary, merged December 2016)
Key Partnerships:Large European pharmaceutical company (CDMO supply contract, $102M value, 2024+), Domestic biopharmaceutical company (GLP-1 innovative drug API CDMO), SK Pharmteco (Preferred Partner)
COMPETITION
Position:Leader
Competitors:Lonza Group, Farmatec (South Korea), Bachem, Cambrex, Other Chinese CDMOs
LEADERSHIP
Key Executives:
Zhao Dezhong - Actual Controller/Vice Chairman (ex-)
Scientific Founders:Zi Quan Tong (Founder, 2009)
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Sinopep-Allsino Biopharmaceutical Co., Ltd. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Sinopep-Allsino Biopharmaceutical Co., Ltd.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.